UK signs deal for 50million doses of Covid vaccines to target potentially jab-resistant variants
UK signs deal for 50million doses of Covid vaccines to target potentially jab-resistant variants – as Oxford insists its jab still works against the Kent variant
- New strains have sparked fears they could dodge immunity from current jabs
- But ministers have now set out a deal to keep the UK a step ahead of the strains
- They have reached a deal with CureVac to make shots against the new variants
- Officials are yet to reveal which they are targeting in the programme
- But it is thought to be likely to include the South African variant of the virus
The UK today rubber-stamped a deal for 50million doses of tweaked coronavirus vaccines, as it steps up efforts to fight off jab-resistant variants.
Newly-emerged strains have sparked concerns across the world, after tests revealed some may be able to dodge immunity triggered by the current crop of vaccines.
But the deal signed between No10 and German biotech firm CureVac today seeks to bolster the UK’s arsenal against these emerging threats, and keep the nation one step ahead of the virus.
Officials are yet to confirm which strains they are targeting, but it is thought likely to include the South African variant which scientific tests show may make jabs slightly less effective.
The vaccines will be based on mRNA, the same technology used by Pfizer/BioNTech for their shots which were more than 90 per cent effective in trials.
Matt Hancock heralded the agreement as ensuring the UK can continue to ‘provide everyone with a high level of protection against the virus and save lives’.
Professor Jonathan Van-Tam, England’s deputy chief medical officer, said new jabs will be needed to ‘offer the best protection possible’ as the virus continues to mutate.
‘Being able to create these new vaccines at speed will allow our scientists to keep ahead of the virus as they do every year with the influenza vaccine,’ he said.
CureVac has been working on an mRNA vaccine – using a protein from the virus – which is currently in stage three trials.
The European Union signed a deal for up to 405million doses of their jab in November, following five months of talks. But the UK did not have any previous purchase commitments with the company.
It comes as research today found the Oxford/AstraZeneca coronavirus vaccine is just as effective at fighting the UK variant as it is the original virus.
Officials haven’t said which variants they are targeting, but it is thought likely to include the South African variant which has sparked door-to-door testing in parts of the UK. Pictured, a policeman delivers a coronavirus testing kit in Maidstone, Kent
The three Covid variants causing international alarm emerged in Britain, South Africa and Brazil
Officials at the Department of Business said an expert advisory group will be established to identify variants for CureVac to target.
They added that the agreement means any tweaked vaccines can quickly be manufactured at scale in the UK and rushed to vaccination centres.
The Health Secretary said: ‘The vaccines we are deploying now are safe and effective, with the latest evidence suggesting they provide protection against new strains of Covid.
‘But we must be prepared for all eventualities and bolster onshore UK manufacturing capacity to develop vaccines to combat new variants of the disease, taking advantage of our world-leading genomics expertise.
‘This will help ensure we can continue to provide everyone with a high level of protection against the virus and save lives.’
Vaccines minister Nadhim Zahawi praised the deal as ‘exactly the kind of work that will stand us in good stead as we continue our monumental national effort to end this pandemic and return to normality’.
‘Of course we urge people to continue to take up the chance to have a vaccine when they are invited to – all of which are safe and have been proven to be effective against the virus.’
The price tag of the new partnership has not been revealed.
There are three main variants of concern at present, with two – the Kent and South African variants – already identified in the UK.
The Kent strain, which is more infectious, has become the dominant one in the country, while 150 cases of the South African one have been identified.
Whole postcodes are currently locked down as officials conduct door-to-door swabbing in an effort to track down any cases of the South African variant to snuff it out before it triggers an outbreak.
Ministers say they believe the Kent variant is susceptible to the current vaccines, but they are concerned the South African one may be able to dodge it in some cases.
There is also a Brazilian variant, which has sparked further concern among ministers after a large outbreak in Manaus state, where it was thought levels of protection against the old strain were already high.
The partnership was signed with German biotech company CureVac. Above is a sign to a Covid-19 testing centre in Walsall, Staffordshire
It comes as research today found the Oxford/AstraZeneca coronavirus vaccine is just as effective at fighting the UK variant as it is the original virus.
Oxford University researchers who developed the vaccine say it has a similar efficacy against the variant, compared with the original strain of Covid-19 against which it was tested.
Experts had been concerned about whether or not the vaccines currently being administered throughout the UK would be effective against the strain that emerged after trials had been conducted.
The preprint also describes analysis which suggests vaccination with the Oxford/AstraZeneca jab results in a reduction in the duration of shedding and viral load, which may translate into a reduced transmission of the disease.
Professor Andrew Pollard, chief investigator on the Oxford vaccine trial, said: ‘Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus, but also protects against the novel variant, B117, which caused the surge in disease from the end of 2020 across the UK.’
The pre-print from Oxford, which is yet to be peer-reviewed, found that vaccine efficacy against symptomatic positive infection was similar for the new UK variant and the previous strain, at 74.6 per cent and 84 per cent respectively.
Professor Pollard said it was not possible to say whether the efficacy levels were the same or different because of overlapping confidence intervals.
He added: ‘The important issue is that it’s in a very similar ballpark to the previously reported efficacy and they’re very similar to each other.
‘We can’t actually say statistically whether those numbers are actually different. If they were, it’s a relatively small percentage – it’s still in the high 70s or 80s for both.’
